Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering pH.
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 mL/kg/hour, typically 500-1000 mL over 4-8 hours, adjusted based on serum chloride and pH. Maximum infusion rate: 1 mL/kg/hour.
For adults and children ≥12 years: 10 mL (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 mL (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
None Documented
None Documented
Variable; approximately 2-4 hours depending on renal function and acid-base status; prolonged in renal impairment.
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Renal: >95% as ammonium and chloride ions; minimal biliary/fecal elimination.
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant/Antitussive Combination